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Accumulating evidence shows that H2S has physiological functions in various tissues and
organs. It includes regulation of neuronal activity, vascular tension, a release of insulin, and
protection of the heart, kidney, and brain from ischemic insult. H2S is produced by enzymes
from L-cysteine; cystathionine β-synthase, cystathionine γ-lyase, and 3-mercaptopyruvate
sulfurtransferase (3MST) along with cysteine aminotransferase. We recently discovered
an additional pathway for the production of H2S from D-cysteine. D-Amino acid oxidase
provides 3-mercaptopyruvate for 3MST to produce H2S. D-Cysteine protects cerebellar
neurons from oxidative stress and attenuates ischemia-reperfusion injury caused in the
kidney more effectively than L-cysteine. This review focuses on a novel pathway for the
production of H2S and its therapeutic application especially to the renal diseases.
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INTRODUCTION
The discovery of endogenous sulfide in the brain urged us to study
the function of hydrogen sulfide (H2S) in the brain (1–3). The
recent re-evaluation showed that the endogenous levels of H2S
are much lower than those initially evaluated, but this finding
confirmed the existence of sulfide in tissues (4–6).
H2S facilitates the induction of hippocampal long-term poten-
tiation, a synaptic model of learning and memory, by enhancing
the activity of n-methyl-d-aspartate (NMDA) receptors in neu-
rons, and it induces Ca2+ waves in astrocytes (7, 8). It relaxes
vascular smooth muscle by activating K+ channels, regulates
the release of insulin and induces angiogenesis (9–14). It pro-
tects neurons from oxidative stress by enhancing the activity
of glutathione synthesis, scavenging reactive oxygen species, and
suppressing the excessive increase in the intracellular Ca2+ (15–
17). In cardiovascular system, H2S protects cardiomyocytes from
ischemia-reperfusion injury by preserving mitochondrial func-
tion (18). A similar protective effect was also observed in the
kidney (19). H2S is produced from l-cysteine by two pyridoxal 5′-
phosphate (PLP)-dependent enzymes, cystathionine β-synthase
(CBS), and cystathionine γ-lyase (CSE) and PLP-independent
3-mercaptopyruvate sulfurtransferase (3MST) (Figure 1) (7, 9,
20–23). 3MST produces H2S from 3-mercaptopyruvate (3MP), an
achiral α-keto acid, which is generated by PLP-dependent cysteine
aminotransferase (CAT) from l-cysteine and α-ketoglutarate (α-
KG) (24–26). Thioredoxin (Trx) and dihydrolipoic acid (DHLA)
are endogenous reducing cofactors that facilitate H2S release
from 3MST (23). We recently discovered a novel pathway with
d-cysteine as a substrate (27).
PRODUCTION OF H2S FROM D-CYSTEINE
When we examined the production of H2S from brain
homogenates, we found that H2S was produced from d-cysteine,
originally used as a negative control for l-cysteine (27). H2S-
producing pathway from d-cysteine is distinct from the pathways
involving l-cysteine. There are critical differences between the two
pathways; (i) the optimal pH, (ii) the dependency on PLP, and (iii)
the stability against the freeze and thaw procedure. The production
of H2S from d-cysteine is optimal at pH 7.4, whereas produc-
tion from l-cysteine is maximal under the alkaline condition. H2S
production from d-cysteine is PLP-independent, while that from
l-cysteine is PLP-dependent. A single freeze-thaw cycle greatly
increases the H2S production from d-cysteine. d-Amino acid oxi-
dase (DAO) that produces 3MP from d-cysteine is localized to
peroxisomes, while 3MST is mainly found in mitochondria (21,
28). Mitochondria and peroxisomes exchange various metabolites
via a specific form of vesicular trafficking, and are usually in close
proximity to each other or have physical contact (29). 3MST and
DAO can produce H2S by the interaction of both organelles.
LOCALIZATION OF H2S-PRODUCING ENZYMES
Enzymes producing H2S from l-cysteine are expressed in many
tissues (7, 9, 17, 20, 21, 23, 30, 31). 3MST is found in neurons in
the cerebral cortex, cerebellum, olfactory bulb, pons, and retina,
while CBS is preferentially expressed in cerebellar Bergmann glia
and in astrocytes throughout the brain (21, 32). CSE activity in
the brain is only 1% of the hepatic activity (33). CBS, CSE and
3MST, and CAT are expressed in the liver and kidney (20). Vascular
endothelium co-expresses 3MST and CAT (31). The localization
of CSE in vascular endothelium is controversial (31, 34). Unlike
the l-cysteine pathways, thed-cysteine pathway operates predomi-
nantly in the cerebellum and the kidney (27, 35). In the cerebellum,
DAO is expressed in astrocytes, Bergmann glia, and several types
of neurons including the Golgi and Purkinje cells (35, 36). In the
kidney, DAO and 3MST are expressed in the proximal convoluted
tubules of the cortex similarly to CBS and CSE (30, 37–39).
REGULATION OF H2S-PRODUCING ENZYMES BY CA2+
3MST/CAT is regulated by Ca2+; the activity is maximal in
the absence of Ca2+ and is completely suppressed at 2.9µM
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FIGURE 1 | Schematic representation of H2S-producing pathways.
Cystathionine β-synthase (CBS) catalyzes β-replacement of L-cysteine to
produce H2S and L-cystathionine. Cystathionine γ-lyase (CSE) catalyzes the
hydrolysis of L-cysteine. 3-Mercaptopyruvate sulfurtransferase (3MST)
produces H2S from 3-mercaptopyruvate (3MP), which is generated by
cysteine aminotransferase (CAT) and D-amino acid oxidase (DAO) from
L-cysteine and D-cysteine, respectively. Thioredoxin (Trx) and dihydrolipoic
acid (DHLA) are endogenous reducing cofactors that facilitate the release
of H2S from 3MST. H2S is stored as bound sulfane sulfur, which is divalent
sulfur bound only to other sulfur, such as outer sulfur atoms of persulfides
and innerchain atoms of polysulfides. Red asterisks show bound sulfane
sulfur.
Ca2+ (17). A similar regulation by Ca2+ is observed in CSE
activity (40). H2S is produced by CSE at the steady-state low
Ca2+ concentrations and that the production is suppressed by
increased Ca2+ (40). Calmodulin is not involved in the reg-
ulation of CSE activity. It was previously reported that CSE
activity is regulated by Ca2+/calmodulin in the presence of 1–
2 mM Ca2+ (34). Because the intracellular Ca2+ concentrations
are between 100 nM and 3µM in endothelium, Ca2+ concen-
trations used in the previous study are not in the physiological
range (41).
SOURCE OF D-CYSTEINE
Relatively large amounts of d-serine are found in mammalian
tissues, and the content of d-serine is up to 15∼ 30% of the
l-form in the brain (42, 43). d-Serine is thought to be pro-
duced by PLP-dependent serine racemase, but the Michaelis-
constant value of serine racemase is higher than the endoge-
nous levels of l-serine (42, 44–46). Although cysteine is struc-
turally similar to serine with an OH replaced by an SH, ser-
ine racemase does not change l-cysteine to d-cysteine (27).
Aspartate racemase is homologous to CAT and has an affinity
for both aspartate and cysteine (24, 47), but does not produce
d-cysteine.
A possible source of d-cysteine is absorption from food. l-
Amino acids are non-enzymatically racemized by heat and alkaline
treatment applied during food processing. l-Cysteine is one of
the fastest racemizing amino acid, and 21–44% of l-cysteine is
changed to d-cysteine by alkaline treatment (48, 49). Although d-
cysteine is easily absorbed through the gastrointestinal tract and
enters the blood stream (50), d-cysteine is not detected either in
the cerebellum or the kidney after the oral administration. Con-
sidering the fact that the levels of bound sulfane sulfur, a storage
form of H2S (Figure 1), are increased after oral administration of
d-cysteine (5, 27), d-cysteine may be immediately metabolized to
produce bound sulfane sulfur in tissues.
CYTOPROTECTIVE EFFECT OF D-CYSTEINE
The most characteristic feature of the d-cysteine pathway is the
greater H2S-producing activity in the cerebellum and the kid-
ney compared to the l-cysteine pathway; 7- and 80-fold greater
in the cerebellum and the kidney, respectively. Although both d-
cysteine and l-cysteine protect cerebellar neurons from hydrogen
peroxide-induced oxidative stress (27), d-cysteine protected neu-
rons more greatly than l-cysteine, probably because the transport
activity for d-cysteine is greater than that for l-cysteine (51).
d-Cysteine may have a potential to improve the developmental
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neuronal diseases in the cerebellum like autism in which oxidative
stress may be involved (52, 53).
Ischemia-reperfusion injury is observed after cardiovascular
surgery, transplantation, or septic as well as hemorrhagic shock.
Renal ischemia-reperfusion injury reduces the filtering capacity
of the glomerulus and causes acute renal failure (54). Endothe-
lin antagonists, atrial natriuretic peptides, prostaglandins, nitric
oxide inhibitors, thyroxine, and human insulin-like growth factor
1 have been studied for the prophylaxis and treatment of acute
tubular necrosis without clinical benefit (55–58). We found that
the oral administration of d-cysteine attenuates renal ischemia-
reperfusion injury (27). The structure of glomeruli, which is
disintegrated after ischemia-reperfusion, is well preserved by d-
cysteine. In contrast, the glomeruli are shrunk and a wide space
is observed between glomerulus and the surrounding capsule
after ischemia-reperfusion when l-cysteine is applied. d-Cysteine
increases the levels of bound sulfane sulfur and protects the renal
cortex from the ischemia-reperfusion injury more efficiently than
l-cysteine.
D-CYSTEINE: ITS THERAPEUTIC POTENTIAL
l-Cysteine is metabolized to produce (i) cysteinyl-tRNA
by cysteinyl-tRNA synthetase (59), (ii) γ-glutamylcysteine, a
precursor of glutathione, by γ-glutamylcysteine synthetase, (iii)
taurine or pyruvate by cysteine dioxygenase (60), and (iv) pro-
pionyl CoA by α-keto acid dehydrogenase. Because d-cysteine is
not metabolized by these enzymes, d-cysteine must efficiently be
utilized to produce H2S in the cerebellum and the kidney.
l-Cysteine is an excitotoxin comparable in potency to other
excitatory amino acids and increases the blood pressure and heart
rate (61, 62). In contrast, d-cysteine neither causes excitotoxic
damage to the brain nor disturbs heart function (63, 64). There-
fore,d-cysteine can be systemically and repeatedly applied with less
toxicity compared to l-cysteine. The administration of d-cysteine
may provide a new therapeutic approach to protect specific tissues
from oxidative stress or ischemia-reperfusion injury through its
conversion to H2S via a novel pathway with 3MST and DAO.
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